Your browser doesn't support javascript.
loading
SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
Murhekar, Manoj V; Bhatnagar, Tarun; Selvaraju, Sriram; Saravanakumar, V; Thangaraj, Jeromie Wesley Vivian; Shah, Naman; Kumar, Muthusamy Santhosh; Rade, Kiran; Sabarinathan, R; Asthana, Smita; Balachandar, Rakesh; Bangar, Sampada Dipak; Bansal, Avi Kumar; Bhat, Jyothi; Chopra, Vishal; Das, Dasarathi; Deb, Alok Kumar; Devi, Kangjam Rekha; Dwivedi, Gaurav Raj; Khan, S Muhammad Salim; Kumar, C P Girish; Kumar, M Sunil; Laxmaiah, Avula; Madhukar, Major; Mahapatra, Amarendra; Mohanty, Suman Sundar; Rangaraju, Chethana; Turuk, Alka; Baradwaj, Dinesh Kumar; Chahal, Ashrafjit S; Debnath, Falguni; Haq, Inaamul; Kalliath, Arshad; Kanungo, Srikanta; Kshatri, Jaya Singh; Lakshmi, G G J Naga; Mitra, Anindya; Nirmala, A R; Prasad, Ganta Venkata; Qurieshi, Mariya Amin; Sahay, Seema; Sangwan, Ramesh Kumar; Sekar, Krithikaa; Shukla, Vijay Kumar; Singh, Prashant Kumar; Singh, Pushpendra; Singh, Rajeev; Varma, Dantuluri Sheethal; Viramgami, Ankit; Panda, Samiran.
Afiliación
  • Murhekar MV; Indian Council of Medical Research (ICMR) National Institute of Epidemiology, Chennai, India. Electronic address: mmurhekar@gmail.com.
  • Bhatnagar T; Indian Council of Medical Research (ICMR) National Institute of Epidemiology, Chennai, India.
  • Selvaraju S; ICMR National Institute for Research in Tuberculosis, Chennai, India.
  • Saravanakumar V; Indian Council of Medical Research (ICMR) National Institute of Epidemiology, Chennai, India.
  • Thangaraj JWV; Indian Council of Medical Research (ICMR) National Institute of Epidemiology, Chennai, India.
  • Shah N; Indian Council of Medical Research (ICMR) National Institute of Epidemiology, Chennai, India.
  • Kumar MS; Indian Council of Medical Research (ICMR) National Institute of Epidemiology, Chennai, India.
  • Rade K; WHO Country Office for India, New Delhi, India.
  • Sabarinathan R; Indian Council of Medical Research (ICMR) National Institute of Epidemiology, Chennai, India.
  • Asthana S; ICMR National Institute of Cancer Prevention and Research, Noida, India.
  • Balachandar R; ICMR National Institute of Occupational Health, Ahmedabad, India.
  • Bangar SD; ICMR National AIDS Research Institute, Pune, India.
  • Bansal AK; ICMR National JALMA Institute for Leprosy and Other Mycobacterial Diseases, Agra, India.
  • Bhat J; ICMR National Institute of Research in Tribal Health, Jabalpur, India.
  • Chopra V; State Tuberculosis Training, Demonstration Centre (STDC), Punjab, India.
  • Das D; ICMR Regional Medical Research Centre, Bhubaneswar, India.
  • Deb AK; ICMR National Institute of Cholera and Enteric Diseases, Kolkata, India.
  • Devi KR; ICMR Regional Medical Research Centre, Northeast Region, Dibrugarh, India.
  • Dwivedi GR; ICMR Regional Medical Research Centre, Gorakhpur, India.
  • Khan SMS; Department of Community Medicine, Government Medical College, Srinagar, India.
  • Kumar CPG; Indian Council of Medical Research (ICMR) National Institute of Epidemiology, Chennai, India.
  • Kumar MS; STDC, Thiruvananthapuram, India.
  • Laxmaiah A; ICMR National Institute of Nutrition, Hyderabad, India.
  • Madhukar M; ICMR Rajendra Memorial Research Institute of Medical Sciences, Patna, India.
  • Mahapatra A; ICMR Regional Medical Research Centre, Bhubaneswar, India.
  • Mohanty SS; ICMR National Institute for Implementation Research on Non-Communicable Diseases, Jodhpur, India.
  • Rangaraju C; National Tuberculosis Institute, Bangalore, India.
  • Turuk A; ICMR, New Delhi, India.
  • Baradwaj DK; ICMR National Institute of Nutrition, Hyderabad, India.
  • Chahal AS; State Tuberculosis Training, Demonstration Centre (STDC), Punjab, India.
  • Debnath F; ICMR National Institute of Cholera and Enteric Diseases, Kolkata, India.
  • Haq I; Department of Community Medicine, Government Medical College, Srinagar, India.
  • Kalliath A; STDC, Thiruvananthapuram, India.
  • Kanungo S; ICMR Regional Medical Research Centre, Bhubaneswar, India.
  • Kshatri JS; ICMR Regional Medical Research Centre, Bhubaneswar, India.
  • Lakshmi GGJN; Office of Joint Director for Tuberculosis, Directorate of Public Health and Family Welfare, Andhra Pradesh, India.
  • Mitra A; STDC, Jharkhand, India.
  • Nirmala AR; Lady Willingdon State Tuberculosis Centre, Government of Karnataka, Bengaluru, India.
  • Prasad GV; Office of Joint Director for Tuberculosis, Directorate of Public Health and Family Welfare, Andhra Pradesh, India.
  • Qurieshi MA; Department of Community Medicine, Government Medical College, Srinagar, India.
  • Sahay S; ICMR National AIDS Research Institute, Pune, India.
  • Sangwan RK; ICMR National Institute for Implementation Research on Non-Communicable Diseases, Jodhpur, India.
  • Sekar K; ICMR National Institute for Research in Tuberculosis, Chennai, India.
  • Shukla VK; Directorate Health Services, Raipur, India.
  • Singh PK; ICMR National Institute of Cancer Prevention and Research, Noida, India.
  • Singh P; ICMR National Institute of Research in Tribal Health, Jabalpur, India.
  • Singh R; ICMR Regional Medical Research Centre, Gorakhpur, India.
  • Varma DS; Office of Joint Director for Tuberculosis, Directorate of Public Health and Family Welfare, Andhra Pradesh, India.
  • Viramgami A; ICMR National Institute of Occupational Health, Ahmedabad, India.
  • Panda S; ICMR, New Delhi, India.
Lancet Glob Health ; 9(3): e257-e266, 2021 03.
Article en En | MEDLINE | ID: mdl-33515512
ABSTRACT

BACKGROUND:

The first national severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurvey in India, done in May-June, 2020, among adults aged 18 years or older from 21 states, found a SARS-CoV-2 IgG antibody seroprevalence of 0·73% (95% CI 0·34-1·13). We aimed to assess the more recent nationwide seroprevalence in the general population in India.

METHODS:

We did a second household serosurvey among individuals aged 10 years or older in the same 700 villages or wards within 70 districts in India that were included in the first serosurvey. Individuals aged younger than 10 years and households that did not respond at the time of survey were excluded. Participants were interviewed to collect information on sociodemographics, symptoms suggestive of COVID-19, exposure history to laboratory-confirmed COVID-19 cases, and history of COVID-19 illness. 3-5 mL of venous blood was collected from each participant and blood samples were tested using the Abbott SARS-CoV-2 IgG assay. Seroprevalence was estimated after applying the sampling weights and adjusting for clustering and assay characteristics. We randomly selected one adult serum sample from each household to compare the seroprevalence among adults between the two serosurveys.

FINDINGS:

Between Aug 18 and Sept 20, 2020, we enrolled and collected serum samples from 29 082 individuals from 15 613 households. The weighted and adjusted seroprevalence of SARS-CoV-2 IgG antibodies in individuals aged 10 years or older was 6·6% (95% CI 5·8-7·4). Among 15 084 randomly selected adults (one per household), the weighted and adjusted seroprevalence was 7·1% (6·2-8·2). Seroprevalence was similar across age groups, sexes, and occupations. Seroprevalence was highest in urban slum areas followed by urban non-slum and rural areas. We estimated a cumulative 74·3 million infections in the country by Aug 18, 2020, with 26-32 infections for every reported COVID-19 case.

INTERPRETATION:

Approximately one in 15 individuals aged 10 years or older in India had SARS-CoV-2 infection by Aug 18, 2020. The adult seroprevalence increased approximately tenfold between May and August, 2020. Lower infection-to-case ratio in August than in May reflects a substantial increase in testing across the country.

FUNDING:

Indian Council of Medical Research.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 / Anticuerpos Antivirales Tipo de estudio: Diagnostic_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Lancet Glob Health Año: 2021 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 / Anticuerpos Antivirales Tipo de estudio: Diagnostic_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Lancet Glob Health Año: 2021 Tipo del documento: Article